RecruitingPhase 4NCT05802849

Acetazolamide Per os for Decompensation of Heart Failure

Sponsor

Samara State Medical University

Enrollment

400 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

Chronic Heart Failure

Summary

The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF), while its prevalence is progressively increasing annually. Acute decompensation of CHF is understood as a rapid increase in the severity of clinical manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial hypotension), which caused urgent medical treatment and emergency hospitalization in a patient already suffering from CHF. Decompensation of CHF requires intensification of treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in addition to standard therapy helps to reduce edematous syndrome.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether adding acetazolamide (a mild diuretic pill taken by mouth) to standard IV diuretic treatment helps people hospitalized for worsening heart failure get rid of excess fluid more effectively. **You may be eligible if:** - You are 18 or older - You have been admitted to the hospital with worsening heart failure requiring IV diuretics (water pills given through a drip) - You have any level of heart pumping function (both reduced and preserved ejection fraction are allowed) - You are willing and able to sign an informed consent form **You may NOT be eligible if:** - You have taken acetazolamide in the month before your hospital admission - You are likely to need strong IV heart medications (inotropes or vasopressors) - Your blood pressure is very low (under 90 mmHg systolic) - Your potassium or sodium levels are too low - You have severe kidney failure or are on dialysis - You have a known allergy to acetazolamide or sulfa-type drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAcetazolamide

Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.